文献速递类风湿关节炎

类风湿关节炎患者启动托法替布与生物制剂DMARDs后严重感染住院风险的多数据库队列研究

Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study.
PubMed 文献 · Lancet Rheumatol · 2020-01-13

托法替布较依那西普、阿巴西普、戈利木单抗、托珠单抗的严重感染风险有升高趋势,与阿达木单抗和培塞利珠单抗相似,低于英夫利西单抗,且带状疱疹风险较所有生物制剂DMARDs高约2倍。

要点

  • 托法替布与阿达木单抗、培塞利珠单抗风险相似,低于英夫利西单抗。
  • 托法替布带状疱疹风险较所有生物制剂DMARDs高约2倍。

核心结论

  • 托法替布与多种生物制剂DMARDs在严重感染住院风险上存在潜在差异,且带状疱疹风险较所有生物制剂DMARDs高约2倍。

研究设计与样本

  • 多数据库队列研究,利用美国Medicare(2012-15)、Optum Clinformatics(2012-18)和IBM MarketScan(2012-17)保险数据库。
  • 通过倾向评分逆概率治疗加权调整60余个混杂因素,各数据库aHR用固定效应荟萃分析合并。

主要发现

  • 托法替布带状疱疹风险较所有生物制剂DMARDs高约2倍。

关键数值与推荐

  • 主要结局为因严重感染(细菌、病毒或机会性感染)住院的复合终点,基于住院主要诊断编码。
  • 次要结局为各类型严重感染和带状疱疹。

临床怎么用

  • 对类风湿关节炎患者选择托法替布或生物制剂DMARDs时,应结合严重感染和带状疱疹风险进行个体化权衡。
  • 托法替布较依那西普严重感染住院风险升高,较英夫利西单抗降低,与阿达木单抗和培塞利珠单抗相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The risk of serious infection is a major concern when prescribing a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. Little evidence exists with regard to serious infection risk associated with tofacitinib, a targeted synthetic (ts)DMARD, compared with biologic DMARDs (bDMARDs) among patients with rheumatoid arthritis. We compared the risk of serious infection in patients with rheumatoid arthritis initiating tofacitinib versus one of the seven bDMARDs. METHODS: In this multidatabase cohort study, we identified eight mutually exclusive groups of patients with rheumatoid arthritis initiating tofacitinib or one of the seven bDMARDs using US public (Medicare 20012-15) and private (Optum Clinformatics 2012-18 and IBM MarketScan 2012-17) health insurance programmes. Eligible patients were aged 18 years or older, and had one inpatient visit or two or more outpatient visits (7-365 days apart) for rheumatoid arthritis using International Classification of Diseases 9th and 10th revision codes. The primary outcome was a composite endpoint of admission to hospital for serious infection including bacterial, viral, or opportunistic infection based on the inpatient principal diagnosis code. Secondary outcomes were individual types of serious infections and herpes zoster. We adjusted for more than 60 potential confounders through propensity score-based inverse probability treatment weighting in each database. Database-specific adjusted hazard ratios (aHRs) were combined using a fixed-effects meta-analysis. FINDINGS: We identified 130 718 patients with rheumatoid arthritis across the three databases. During 100 790 person-years of follow-up, 3140 serious infections occurred (crude incidence rate per 100 person-years 3·12, 95% CI 3·01-3·23). The aHR for serious infection associated with tofacitinib was 1·41 (95% CI 1·15-1·73) versus etanercept, 1·20 (0·97-1·49) versus abatacept, 1·23 (0·94-1·62) versus golimumab, and 1·17 (0·89-1·53) versus tocilizumab. The serious infection risk with tofacitinib was similar to adalimumab (1·06, 0·87-1·30) and certolizumab (1·02, 0·80-1·29), and was lower than infliximab (0·81, 0·65-1·00). Tofacitinib was associated with a 2-fold higher risk of herpes zoster versus all bDMARDs. INTERPRETATION: This study found potential differences between tofacitinib and several bDMARDs in the risk of admission to hospital for serious infection, as well as herpes zoster, in patients with rheumatoid arthritis. These results contribute to the evolving understanding of the overall risk-benefit profile of tofacitinib. FUNDING: Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Harvard University, MA, USA.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Pawar A, Desai RJ, Gautam N, et al. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020. PMID: 38263664. doi:10.1016/S2665-9913(19)30137-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。